LPTX leaptx.com: Enterprise Value to EBITDA Ratio

Graphic logo of Leap Therapeutics (LPTX)

Leap Therapeutics, Inc. (LPTX) relies on a fabless model, outsourcing molecule synthesis and testing to external contractors. The business is founded on proprietary antibody developments for the therapy of gastrointestinal tumors. This price chart, with an EV/EBITDA metric at , is supplemented by data on combinatorial gastric cancer studies, while the current market price already prices in the existing liquidity reserve and R&D risks.

Leap Therapeutics Inc - LPTX Total Company Value to Operating Income Before Depreciation Ratio (period 07/04/2022 - 11/16/2026)

Summary analytical data breakdowns for Leap Tx (LPTX)

- stock price and consensus target price:
Fundamental company analysis:LPTX (Leap Therapeutics Inc)
Original product of Leap Therapeutics Inc

For an investor, analyzing the resilience of Leap Therapeutics, Inc. (LPTX) requires weighing asset value against the actual ability to generate cash flow amidst the costly clinical trials of cancer immunotherapy. The EV/EBITDA metric reflects the ratio of total enterprise value to earnings before depreciation and amortization, allowing for an assessment of capital management efficiency during the scaling phase of the antibody portfolio.

Competitor analysis for Leap Therapeutics, Inc.

ImmunityBio Inc - Enterprise Value to EBITDA Ratio|Immunocore (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (Arcus Biosciences)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iovance.com|Enterprise Value to EBITDA Ratio immatics.com (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor Inc (XNCR)|Enterprise Value to EBITDA Ratio Compass Bio CMPX|Replimune Group Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell Pharma LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology) - Enterprise Value to Operating Income Before Depreciation|cgen.com (CGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA IO Biotech Corp (IOBT)|Enterprise Value to EBITDA Ratio STRO|INKT - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio HOWL (Werewolf Therapeutics)|Enterprise Value to Operating Income Before Depreciation Ratio IMMX|EV/EBITDA Multiple ALXO (ALX Oncology)|cuebiopharma.com (CUE) - Company Value to EBITDA|PDS Biotechnology Corp - EV/EBITDA Multiple|Company Value to EBITDA Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Liminatus Pharma - Business Value to Operating Income Before Depreciation|LVTX (Lava Tx) - EV/EBITDA Multiple|EV/EBITDA Multiple NextCure Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization intensitytherapeutics.com (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Theriva Biologics Inc - Enterprise Value to EBITDA Ratio|Gritstone Bio (GRTS) - Company Value to EBITDA|KA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NEXI (NexImmune) - Enterprise Value to Operating Income Before Depreciation|TSBX (Turnstone Biologics Corp.) - Enterprise Value to EBITDA Ratio|Vaccinex, Inc (VCNX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Therapeutics